Clinical Trial Update: Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing antibody persistence and response to re-vaccination with Menactra or Menomune three years after initial meningococcal vaccinati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Disease
• Meningococcal Meningitis

Drugs mentioned

• Menactra (Meningococcal conjugate vaccine (A, C, W, Y))
• Menomune (Meningococcal polysaccharide vaccine (serogroups A, C, W, Y))

Snippet

Sponsor: Sanofi | Conditions: Meningitis, Meningococcal Meningitis | Phase 2 | Status: COMPLETED | Results posted: 2012-06-19